Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2015, Vol. 44 Issue (4): 458-464    DOI: 10.3785/j.issn.1008-9292.2015.07.17
综述     
麻疹病毒抗肿瘤作用的研究进展
周朵, 赵正言
浙江大学医学院附属儿童医院儿保科, 浙江 杭州 310003
Advances in measles virus for cancer therapy
ZHOU Duo, ZHAO Zheng-yan
Pediatric Health Care Department, the Children's Hospital Zhejiang University School of Medicine, Hangzhou 310003, China
全文: PDF(759 KB)  
摘要: 

麻疹病毒能够选择性感染和杀伤多种肿瘤细胞,其中麻疹病毒疫苗株主要通过结合膜辅蛋白、脊髓灰质炎病毒样受体-4进入细胞.研究证实,麻疹病毒疫苗株在体内外对多种肿瘤的生长具有抑制作用.随着生物技术的发展,科学家成功拯救出麻疹病毒疫苗株,并以麻疹病毒疫苗株为基础,在基因水平上对其进行了大量的改造以增强其抗肿瘤能力.目前,麻疹病毒疫苗株治疗卵巢癌、多发性骨髓瘤的一期临床试验已经进行,证实麻疹病毒疫苗株具有潜在的抗肿瘤能力.
关键词 ： 麻疹疫苗/免疫学,  麻疹病毒/免疫学,  抗肿瘤药,  肿瘤/治疗,  综述    
Abstract：

Oncolytic virotherapy is a novel cancer therapy. Vaccine-attenuated strains of measles virus(MV)is an ideal candidate for oncolytic virotherapy which has an excellent safety record. Vaccine-attenuated MV uses CD46 and Nectin-4 molecule as major entry receptors into cells. Vaccine-attenuated MV can selectively infect and kill a wide variety of cancer cells in vitro and in vivo. With the development of molecular cloning, scientists have successfully rescued cDNA of vaccine-attenuated MV and increased its oncolytic efficiency with molecular engineering techniques. Phase I clinical trials of virotherapy for ovarian cancer and multiple myeloma with vaccine-attenuated MV are underway. The preliminary results indicate the promising antitumor potential of vaccine-attenuated MV.
Key words： Measles vaccine/immunology    Measles virus/immunology    Antineoplastic agents    Neoplasms/therapy    Review
收稿日期: 2015-01-27
CLC:  R73  
基金资助:

国家重点基础研究发展计划("973"计划)(2012CB944903)
通讯作者: 赵正言(1953-),男,硕士,主任医师,博士生导师,主要从事儿童保健的基础和临床研究;E-mail:zhaozy@zju.edu.cn;http://orcid.org/0000-0001-8626-2578     E-mail: zhaozy@zju.edu.cn
作者简介: 周朵(1988-),女,硕士研究生,主要从事儿童保健及麻疹病毒抗肿瘤作用的研究;E-mail:21118234@zju.edu.cn;http://orcid.org/0000-0002-6545-5351
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
周朵
赵正言

引用本文:

周朵, 赵正言. 麻疹病毒抗肿瘤作用的研究进展[J]. 浙江大学学报（医学版）, 2015, 44(4): 458-464.
ZHOU Duo, ZHAO Zheng-yan. Advances in measles virus for cancer therapy. Journal of ZheJiang University(Medical Science), 2015, 44(4): 458-464.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2015.07.17      或      http://www.zjujournals.com/xueshu/med/CN/Y2015/V44/I4/458

[1] MSAOUEL P, OPYRCHAL M, DOMINGO MUSIBAY E, et al. Oncolytic measles virus strains as novel anticancer agents[J]. Expert Opin Biol Ther, 2013,13(4):483-502.
[2] RUSSELL S J, PENG K W, BELL J C. Oncolytic virotherapy[J]. Nat Biotechnol, 2012,30(7):658-670.
[3] FIELDING A K. Measles as a potential oncolytic virus[J]. Rev Med Virol, 2005, 15(2):135-142.
[4] GRIFFIN D E, PAN C H.Measles: old vaccines, new vaccines[J]. Curr Top Microbiol Immunol, 2009,330: 191-212.
[5] LECH P J, RUSSELL S J. Use of attenuated paramyxoviruses for cancer therapy[J]. Expert Rev Vaccines, 2010,9(11):1275-1302.
[6] NAVARATNARAJAH C K, OEZGUEN N,RUPP L, et al. The heads of the measles virus attachment protein move to transmit the fusion-triggering signal[J]. Nat Struct Mol Biol, 2011,18(2):128-134.
[7] WILD T F, MALVOISIN E, BUCKLAND R.Measles virus both the haemagglutinin and fusion glycoproteins are required for fusion [J]. J Gen virol, 1991,72(pt 2):439-442.
[8] Centers for Disease Control and Prevention. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection,1993[J]. MMWR Morb Mortal Wkly Rep, 1996,45(28):603-606.
[9] BLUMING A Z, ZIEGLER J L. Regression of Burkitt's lymphoma in association with measles infection[J]. Lancet, 1971,2(7715):105-106.
[10] PASQUINUCCI G. Possible effect of measles on leukaemia[J]. Lancet, 1971,1(7690): 136.
[11] ZYGIERT Z. Hodgkin's disease: remissions after measles[J]. Lancet, 1971,1(7699): 593.
[12] MSAOUEL P, DISPENZIERI A, GALANIS E.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview[J]. Curr Opin Mol Ther, 2009,11(1):43-53.
[13] NAKAMURA T, PENG K W, HARVEY M,et al.Rescue and propagation of fully retargeted oncolytic measles viruses[J]. Nat Biotechnol, 2005,23(2):209-214.
[14] YAIW K C, MIEST T S, FRENZKE M, et al. CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy[J]. Gene Ther, 2011,18(3):313-317.
[15] M Parrula M C, FERNANDEZ S A, LANDES K, et al. Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness[J]. Virus Res, 2014,189:206-213.
[16] THIRUKKUMARAN C M, MORRIS D G. Oncolytic virotherapy for multiple myeloma: past, present,and future[J]. Bone Marrow Res, 2011,2011:632-948.
[17] ZEMP F J, CORREDOR J C, LUN X Q, et al. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil[J]. Cytokine & Growth Factor Rev, 2010,21(2-3):103-117.
[18] LI H, PENG K W, DINGLI D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy[J]. Cancer Gene Ther, 2010,17(8):550-558.
[19] DONNELLY O G, ERRINGTON-MAIS F, STEELE L, et al. Measles virus causes immunogenic cell death in human melanoma[J]. Gene Ther, 2013,20(1):7-15.
[20] HARTKOPF A D, BOSSOW S, LAMPE J, et al. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase[J]. Gynecol Oncol, 2013,130(2):362-368.
[21] IANKOV I D, MSAOUEL P, ALLEN C, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model [J]. Breast Cancer Res Treat, 2010,122(3):745-754.
[22] LIU Y P, STEELE M B, SUKSANPAISAN L, et al. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer[J]. Gynecol Oncol, 2014,132(1): 194-202.
[23] SUGIYAMA T, YONEDA M, KURAISHI T, et al. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment[J]. Gene Ther,2013,20(3):338-347.
[24] LIU C S, HASEGAWA K, RUSSELL S J, et al. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer[J]. Prostate, 2009,69(10):1128-1141.
[25] BOSSOW S, GROSSARDT C, TEMME A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer[J]. Cancer Gene Ther, 2011,18(8):598-608.
[26] XIA M,MENG G, JIANG A, et al. Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus[J]. Oncotarget, 2014,5(11):3907-3918.
[27] BOISGERAULT N, GUILLERME J B, POULIQUEN D, et al. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas[J]. Biomed Res Int, 2013,2013: 387362.
[28] ONG H T, FEDERSPIEL M J, GUO C M, et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth[J]. J Hepatol, 2013,59(5):999-1006.
[29] HSU E C, IORIO C, SARANGI F, et al. CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus[J]. Virology, 2001,279(1):151.
[30] MANCHESTER M, NANICHE D, STEHLE T.CD46 as a measles receptor: form follows function[J]. Virology, 2000,274(1):5-10.
[31] MUHLEBACH M D, MATEO M, SINN P L, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus[J]. Nature, 2011,480(7378):530-533.
[32] PENG K W, TENEYCK C J, GALANIS E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus[J]. Cancer Res, 2002,62(12):4656-4662.
[33] DELPEUT S, NOYCE R S,RICHARDSON C D.The tumor-associated marker,PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses[J]. Viruses, 2014,6(6):2268-2286.
[34] MASSE N, AINOUZE M, NEEL B, et al. Measles virus (MV) hemagglutinin: evidence that attachment sites for MV receptors SLAM and CD46 overlap on the globular head[J]. J Virol, 2004,78(17):9051-9063.
[35] NOYCE R S, BONDRE D G, HA M N, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus[J]. PLoS Pathog, 2011,7(8):e1002240.
[36] ZHANG X, LU G, QI J, et al. Structure of measles virus hemagglutinin bound to its epithelial receptor nectin-4[J]. Nat Struct Mol Biol, 2013,20(1):67-72.
[37] YANAGI Y, TAKEDA M, OHNO S.Measles virus: cellular receptors,tropism and pathogenesis[J]. J Gen Virol, 2006,87(pt 10):2767-2779.
[38] PENG K W, FACTEAU S, WEGMAN T,et al.Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides[J]. Nat Med, 2002,8(5): 527-531.
[39] GALANIS E, HARTMANN L C, CLIBY W A, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer[J]. Cancer Res, 2010,70(3): 875-882.
[40] DINGLI D, PENG K W, HARVEY M E, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter[J].Blood, 2004,103(5):1641-1646.
[41] DADACHOVA E, CARRASCO N.The Na/I symporter(NIS): imaging and therapeutic applications[J]. Semin Nucl Med, 2004,34(1):23-31.
[42] CARLSON S K, CLASSIC K L, HADAC E M, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography[J]. Mol Imaging Biol, 2006,8(6):324-332.
[43] RUSSELL S J, FEDERSPIEL M J, PENG K W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy[J]. Mayo Clin Proc, 2014,89(7):926-933.
[44] HUTZEN B, PIERSON C R, RUSSELL S J,et al.Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine[J]. BMC Cancer, 2012,12: 508.
[45] LIU Y P, STEELE M B, SUKSANPAISAN L, et al. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer[J]. Gynecol Oncol, 2014,132(1):194-202.
[46] OPYRCHAL M, ALLEN C, IANKOV I, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter(MV-NIS)[J].Hum Gene Ther, 2012,23(4):419-427.
[47] GOTOH B, KOMATSU T, TAKEUCHI K, et al. Paramyxovirus accessory proteins as interferon antagonists[J]. Microbiol Immunol, 2001,45(12):787-800.
[48] HARALAMBIEVA I, IANKOV I, HASEGAWA K, et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response[J]. Mol Ther, 2007,15(3): 588-597.
[49] SCHNEIDER U, BULLOUGH F, VONGPUNSAWAD S, et al. Recombinant measles viruses efficiently entering cells through targeted receptors[J]. J Virol, 2000,74(21):9928-9936.
[50] PENG K W, DONOVAN K A, SCHNEIDER U, et al. Oncolytic measles viruses displaying a single-chain antibody against CD38,a myeloma cell marker[J]. Blood, 2003,101(7):2557-2562.
[51] KNEISSL S, ZHOU Q, SCHWENKERT M, et al. CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes[J]. PLoS One, 2013,8(11):e79047.
[52] PENG K W, HOLLER P D, ORR B A, et al. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor[J]. Gene Ther, 2004,11(15):1234-1239.
[53] HEINZERLING L, KUNZI V, OBERHOLZER P A, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells[J]. Blood, 2005,106(7):2287-2294.
[1] 高思倩,沈咏梅,耿福能,李艳华,高建青. 颞叶癫痫与海马成体神经再生[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[2] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 15-21.
[3] 高思倩,沈咏梅,耿福能,李艳华,高建青. 糖尿病溃疡动物模型的建立及相关治疗研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[4] 李文龙,瞿海斌. 近红外光谱应用于中药质量控制及生产过程监控的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 80-88.
[5] 郑艳榕,张翔南,陈忠. Nix介导的线粒体自噬机制的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 92-96.
[6] 封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 655-660.
[7] 李统宇 等. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 648-654.
[8] 夏光发 等. 新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效[J]. 浙江大学学报（医学版）, 2016, 45(6): 614-619.
[9] 曹鹏 等. 双氢青蒿素抗肿瘤分子生物学机制研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 501-507.
[10] 李亭亭 等. 中性粒细胞在哮喘中作用的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 544-549.
[11] 王雪 等. TANK结合激酶1在抗病毒免疫应答中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 550-557.
[12] 杜苗苗 等. 钙化性主动脉瓣疾病药物治疗研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 432-438.
[13] 何斌 等. 贝伐珠单克隆抗体在难治性子宫颈癌中的应用进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 395-402.
[14] 历雪莹 等. DNA甲基化及其靶向治疗在急性髓系白血病中的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 387-394.
[15] 竺天虹 等. 上皮间充质转化介导子宫内膜异位症发生发展的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 439-445.